DIABETES AND HYPOPITUITARISM AS IMMUNE-RELATED ENDOCRINOPATHIES ASSOCIATED WITH PEMBROLIZUMAB THERAPY IN A PATIENT WITH ADVANCED RENAL CELL CARCINOMA
Keywords:
pembrolizumab, diabetes, hypopituitarismAbstract
CASE
We report a 59-year-old Malaysian-Chinese male with bilateral renal cell carcinoma with liver metastases who developed diabetes and hypopituitarism after approximately ten months on pembrolizumab. He presented with a one-week history of lethargy, polyuria, polydipsia, and nocturia. He was admitted to a private hospital as a case of diabetic ketoacidosis and was discharged with basal-bolus insulin. Three days after discharge, he was admitted to the oncology ward for uncontrolled diabetes without ketosis. Blood tests showed high serum glucose, low morning cortisol 11 nmol/L, low ACTH and low testosterone with inappropriately normal FSH and LH. He was diagnosed with diabetes, secondary adrenal insufficiency and hypogonadotropic hypogonadism. His condition improved after administration of basal-bolus insulin and hydrocortisone. He experienced spontaneous recovery of the gonadal axis after three months.
Downloads
References
*
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 DShireen Lui Siow Leng, Azraai Bahari Nasruddin
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The full license is at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).
To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to jafes@asia.com or jafes.editor@gmail.com.
A written agreement shall be emailed to the requester should permission be granted.
